首页> 外文期刊>Colloids and Surfaces, B. Biointerfaces >Polymeric emulsion and crosslink-mediated synthesis of super-stable nanoparticles as sustained-release anti-tuberculosis drug carriers
【24h】

Polymeric emulsion and crosslink-mediated synthesis of super-stable nanoparticles as sustained-release anti-tuberculosis drug carriers

机译:聚合物乳液和交联介导的超稳定纳米粒子的合成作为缓释抗结核药物载体

获取原文
获取原文并翻译 | 示例
           

摘要

This study focused on evaluating four emulsion-based processing strategies for polymeric nanoparticle synthesis to explicate the mechanisms of nanoparticle formation and the influence on achieving sustained-release of two anti-tuberculosis drugs, isoniazid and rifampicin. Poly(lactic-co-glycolic acid) (PLGA) nanoparticles were formulated with and without sorbitan mono-oleate as a stabilizer using emulsion-solvent- surfactant-evaporation (ESSE) and emulsion-solvent-evaporation (ESE) approaches. An alginate solution gelled by ionic crosslinking with calcium chloride was employed to prepare alginate hydrogel nanoparticles via reverse-emulsion-cationic-gelification (RECG) and reverse-emulsion- surfactant-cationic-gelification (RESCG) approaches. In vitro drug release analysis was performed. The size, zeta potential and morphology of the nanoparticles were analyzed. Molecular mechanics energy relationships (MMER) were employed to explore the spatial disposition of alginate and PLGA with respect to the emulsifying profile of sorbitan monooleate and to corroborate the experimental findings. Results revealed that particle size of the PLGA nanoparticles was influenced by the stabilizer concentration. Nanoparticles synthesized by the ESSE approach had smaller sizes of 240 ± 8.7. nm and 195.5 ± 5.4. nm for rifampicin- and isoniazid-loaded nanoparticles, respectively. This was a substantial size reduction from nanoparticles generated by the ESE approach (>1000 nm). The RESCG approach produced stable and higher nanoparticle yields with desirable size (277 ± 1.0. nm; 289 ± 1.2. nm), a low polydispersity index (27.1 ± 0.3. mV; 28.5 ± 0.5. mV) and drug entrapment efficiency of 73% and 75% for isoniazid and rifampicin, respectively. Drug release from the ESSE and RESCG synthesized nanoparticles displayed desirable release of the two anti-TB drugs with sustained zero-order kinetics over a period of 8 h. MMER supported the mechanisms of nanoparticle formation with a sphericalized interlaced network configuration.
机译:本研究重点是评估聚合物纳米颗粒合成的四种基于乳液的加工策略,以促进纳米粒子形成的机制及其对两种抗结核药物,异烟肼和利福平的持续释放的影响。使用乳液 - 溶剂 - 表面活性剂 - 蒸发(ES​​SE)和乳液 - 溶剂蒸发(ES​​E)方法,用脱山梨糖单溶胶用作稳定剂配制聚(乳酸二乙醇酸)(PLGA)纳米颗粒。采用与氯化钙的离子交联凝胶的藻酸盐溶液通过反向乳液 - 阳离子 - 凝胶化(RECG)和反向乳化表面活性剂 - 阳离子 - 凝胶化(RECCG)方法制备海藻酸盐水凝胶纳米颗粒。进行体外药物释放分析。分析了纳米颗粒的尺寸,ζ电位和形态。使用分子力学能量关系(MMER),用于探讨山梨糖醇单烯烃的乳化型材和证实实验结果的乳化型材的空间处理。结果表明,PLGA纳米颗粒的粒度受稳定剂浓度的影响。由ESSE方法合成的纳米颗粒具有240±8.7的尺寸较小。 NM和195.5±5.4。分别为利福平和异壬虫纳米颗粒的NM。这是由ESE方法(> 1000nm)产生的纳米颗粒的大小减少。 RECG方法产生稳定,更高的纳米粒子产率,具有所需的尺寸(277±1.0.nm; 289±1.2.nm),低多分散性指数(27.1±0.3。MV; 28.5±0.5。MV)和药物夹紧效率为73%同种毒素和利福平分别为75%。从ESSE和RECCG的药物释放合成纳米颗粒在8小时的时间内显示出两种抗结核药物的所需释放两种抗TB药物。 MMER支持纳米粒子形成的机制,具有球形的隔行扫描网络配置。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号